{
    "clinical_study": {
        "@rank": "35163", 
        "arm_group": {
            "arm_group_label": "GVHD Regimen", 
            "arm_group_type": "Experimental", 
            "description": "Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT)"
        }, 
        "brief_summary": {
            "textblock": "IL-2 add-back post allogeneic hematopoietic stem cell transplant (HSCT), combined with\n      Sirolimus (SIR), Tacrolimus (TAC) will optimize Treg reconstitution and prevent graft versus\n      host disease (GVHD)."
        }, 
        "brief_title": "In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Graft-Versus-Host-Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "detailed_description": {
            "textblock": "1) Determine if a GVHD prophylaxis regimen of IL-2/SIR/TAC enhances in vivo Treg\n      differentiation and growth; 2) Study the safety and effects of IL-2/SIR/TAC on the incidence\n      of acute and chronic GVHD; 3) Evaluate the influence of dual IL-2 supplementation and\n      mammalian target of rapamycin (mTOR) inhibition on T cell-specific signaling pathways and\n      the polarization of emerging T helper cells."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have an available 8/8 human leukocyte antigen (HLA)-A, -B, -C, and\n             -DRB1 matched-related or unrelated donor allogeneic hematopoietic peripheral blood\n             stem cell graft.\n\n          -  Acute myeloid leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic myeloid\n             leukemia, or myeloproliferative neoplasms requiring a matched allogeneic HSCT.\n\n               -  Acute Leukemia (AML or ALL) must be in complete remission defined as:  <5%\n                  marrow blasts with no morphologic evidence of leukemia, no peripheral blasts,\n                  marrow >20% cellular, and peripheral absolute neutrophil count >1000/\u00b5L\n                  (platelet recovery is not required).\n\n               -  Myelodysplasia (MDS) and chronic myeloid leukemia (CML):  Must have <5% marrow\n                  blasts.\n\n               -  Myeloproliferative neoplasms (MPN):  Must have <5% peripheral / marrow blasts.\n\n          -  Adequate vital organ function:\n\n               1. Left ventricular ejection fraction (LVEF) \u2265 45% by multi gated acquisition\n                  (MUGA) scan\n\n               2. Forced expiratory volume at one second (FEV1), forced vital capacity (FVC), and\n                  diffusing lung capacity oxygenation (DLCO) \u2265 50% of predicted values on\n                  pulmonary function tests\n\n               3. Transaminases (AST, ALT) < 2 times upper limit of normal values\n\n               4. Creatinine clearance \u2265 50 cc/min.\n\n          -  Performance status:  Karnofsky Performance Status Score \u2265 80%\n\n        Exclusion Criteria:\n\n          -  Active infection not controlled with appropriate antimicrobial therapy\n\n          -  History of HIV, hepatitis B, or hepatitis C infection\n\n          -  Anti-thymocyte globulin, alemtuzumab, bortezomib, or cyclophosphamide administered\n             within 14 days before or after HCT\n\n          -  Hypersensitivity to recombinant human IL-2\n\n          -  Chronic lymphocytic leukemia, Hodgkin lymphoma, and non-hodgkin lymphoma are excluded\n             as these malignancies may express the IL-2 receptor and pose a potential growth\n             signal to any present disease.\n\n          -  Sorror's co-morbidity factors with total score >4"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01927120", 
            "org_study_id": "MCC-17578"
        }, 
        "intervention": [
            {
                "arm_group_label": "GVHD Regimen", 
                "description": "A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).", 
                "intervention_name": "IL-2", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Proleukin\u00ae", 
                    "(aldesleukin)"
                ]
            }, 
            {
                "arm_group_label": "GVHD Regimen", 
                "description": "Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "GVHD Regimen", 
                "description": "Orally on day -1.  The dose for loading is 12 mg by mouth (PO)", 
                "intervention_name": "Sirolimus", 
                "intervention_type": "Drug", 
                "other_name": "Rapamune"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interleukin-2", 
                "Sirolimus", 
                "Everolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "GVHD", 
            "Allogeneic", 
            "Hematopoietic Cell Transplant"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "link": {
            "description": "H. Lee Moffitt Cancer Center & Research Institute", 
            "url": "http://www.moffitt.org"
        }, 
        "location": {
            "contact": {
                "email": "Brian.Betts@moffitt.org", 
                "last_name": "Brian Betts, MD", 
                "phone": "813-745-5410"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H. Lee Moffitt Cancer Center and Research Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Brian Betts, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Joseph Pidala, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Claudio Anasetti, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Marcie Riches, MD, MS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Melissa Alsina, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ernesto Ayala, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Teresa Field, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "William Janssen, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Taiga Nishihori, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Frederick Locke, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jose Leonel Ochoa-Bayona, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lia Perez, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mohamed Kharfan-Dabaja, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hugo Fernandez, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis With IL-2, Sirolimus, and Tacrolimus Following Allogeneic Hematopoietic Cell Transplantation", 
        "overall_contact": {
            "email": "Brian.Betts@moffitt.org", 
            "last_name": "Brian Betts, MD", 
            "phone": "813-745-5410"
        }, 
        "overall_official": {
            "affiliation": "Moffitt Cancer Center", 
            "last_name": "Brian Betts, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of Treg among blood CD4+ T cells at day 30 after hematopoietic cell transplantation (HCT)", 
            "measure": "In Vivo Treg Expansion", 
            "safety_issue": "No", 
            "time_frame": "30 days post transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01927120"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}